The Experts below are selected from a list of 412965 Experts worldwide ranked by ideXlab platform
Gianluigi Galizia - One of the best experts on this subject based on the ideXlab platform.
-
Syncope and Epilepsy coexist in 'possible' and 'drug-resistant' Epilepsy (Overlap between Epilepsy and Syncope Study - OESYS).
BMC neurology, 2017Co-Authors: Andrea Ungar, Alice Ceccofiglio, Francesca Pescini, Chiara Mussi, Giovanni Tava, Martina Rafanelli, Assunta Langellotto, Niccolò Marchionni, J. Gert Van Dijk, Gianluigi GaliziaAbstract:Abstract Background Differential diagnosis between syncope and Epilepsy in patients with transient loss of consciousness of uncertain etiology is still unclear. Thus, the aim of the present work is to evaluate the prevalence of syncope in patients with “possible” or “drug-resistant” Epilepsy. Methods The Overlap between Epilepsy and SYncope Study (OESYS) is a multicenter prospective observational study designed to estimate the prevalence of syncope in patients followed in Epilepsy Centers for “possible” or “drug-resistant” Epilepsy and assessed according the European Society of Cardiology (ESC) guidelines of syncope diagnosis. Results One hundred seven patients were evaluated; 63 (58.9%) had possible and 44 (41.1%) drug-resistant Epilepsy. A final diagnosis of isolated syncope was in 45 patients (42.1%), all with possible Epilepsy (45/63, 71.4%). Isolated Epilepsy was found in 21 patients (19.6%) and it was more frequent in the drug-resistant than in the possible Epilepsy group (34.1% vs. 9.5%, p = 0.002). More importantly, syncope and Epilepsy coexisted in 37.4% of all patients but the coexistence was more frequent among patients with drug-resistant than possible Epilepsy (65.9% vs. 17.5%, p Conclusions Isolated syncope was diagnosed in ≈ 70% of patients with possible Epilepsy. Syncope and Epilepsy coexisted in ≈ 20% of patients with possible and in ≈ 60% of patients with drug-resistant Epilepsy. These findings highlight the need of ESC guidelines of syncope approach in patients with possible and drug-resistant Epilepsy.
-
Syncope and Epilepsy coexist in ‘possible’ and ‘drug-resistant’ Epilepsy (Overlap between Epilepsy and Syncope Study - OESYS)
BMC Neurology, 2017Co-Authors: Andrea Ungar, Alice Ceccofiglio, Francesca Pescini, Chiara Mussi, Giovanni Tava, Martina Rafanelli, Assunta Langellotto, Niccolò Marchionni, J. Gert Van Dijk, Gianluigi GaliziaAbstract:Background Differential diagnosis between syncope and Epilepsy in patients with transient loss of consciousness of uncertain etiology is still unclear. Thus, the aim of the present work is to evaluate the prevalence of syncope in patients with “possible” or “drug-resistant” Epilepsy. Methods The Overlap between Epilepsy and SYncope Study (OESYS) is a multicenter prospective observational study designed to estimate the prevalence of syncope in patients followed in Epilepsy Centers for “possible” or “drug-resistant” Epilepsy and assessed according the European Society of Cardiology (ESC) guidelines of syncope diagnosis. Results One hundred seven patients were evaluated; 63 (58.9%) had possible and 44 (41.1%) drug-resistant Epilepsy. A final diagnosis of isolated syncope was in 45 patients (42.1%), all with possible Epilepsy (45/63, 71.4%). Isolated Epilepsy was found in 21 patients (19.6%) and it was more frequent in the drug-resistant than in the possible Epilepsy group (34.1% vs. 9.5%, p = 0.002). More importantly, syncope and Epilepsy coexisted in 37.4% of all patients but the coexistence was more frequent among patients with drug-resistant than possible Epilepsy (65.9% vs. 17.5%, p
Catherine E. Meade - One of the best experts on this subject based on the ideXlab platform.
-
Specificity of psychopathology in temporal lobe Epilepsy.
Epilepsy & Behavior, 2013Co-Authors: Amie Foran, Stephen C. Bowden, Fiona J. Bardenhagen, Mark J. Cook, Catherine E. MeadeAbstract:An investigation into the specificity of psychopathology in temporal lobe Epilepsy was conducted using the Minnesota Multiphase Personality Inventory second edition (MMPI-2) profiles. Consecutive series of patients with left temporal lobe Epilepsy (n = 49) and those with right temporal lobe Epilepsy (n = 45) were compared with patients with other forms of Epilepsy (n = 46) and other heterogeneous neurological conditions (n = 69). The investigation focused on the Clinical, Content, and Subscales scales that resembled descriptions of the Interictal Dysphoric Disorder symptoms and Temporal Lobe Epilepsy Personality Traits. Patients with right temporal lobe Epilepsy and those with left temporal lobe Epilepsy did not have different patterns of scale elevation, nor did they have clinical elevations compared with patients with other types of Epilepsy or neurological controls. The MMPI-2 scales that resemble descriptions of the Interictal Dysphoric Disorder or Temporal Lobe Epilepsy Personality Syndrome were not elevated in either group of patients with temporal lobe Epilepsy compared with the group of patients with non-temporal lobe Epilepsy or heterogeneous neurological controls. This study adds to the mounting body of empirical research that has used standardized measures and matched groups, but failed to detect a special affinity between psychopathology and temporal lobe Epilepsy.
Rosemarie Kobau - One of the best experts on this subject based on the ideXlab platform.
-
People with Epilepsy are diagnosed most often with unspecified Epilepsy, followed by focal Epilepsy, generalized convulsive Epilepsy, and generalized nonconvulsive Epilepsy-US MarketScan data, 2010-2015.
Epilepsy & behavior : E&B, 2017Co-Authors: Sanjeeb Sapkota, Rosemarie Kobau, Daniel M. Pastula, Matthew M. ZackAbstract:The distribution of Epilepsy types varies by age, etiology, provider diagnostic capabilities, and assessment criteria. No recent US study has examined the distribution of Epilepsy types in a large, population-based sample of people with Epilepsy. We used MarketScan data from January 1, 2010 through September 30, 2015, to estimate the proportion of Epilepsy types among all (N=370,570) individuals diagnosed with Epilepsy. We identified cases of Epilepsy as individuals with at least one International Classification of Disease, 9th version (ICD-9) diagnostic code of 345.X and the use of at least one antiseizure drug described in the 2015 MarketScan Redbook. Unspecified Epilepsy was more common (36.8%) than focal-localized Epilepsy (24.6%), generalized convulsive Epilepsy (23.8%), generalized nonconvulsive Epilepsy (8.9%), other forms of Epilepsy (5.2%), infantile spasm (0.3%), and epilepsia partialis continua (0.3%). The high proportion of Epilepsy classified as unspecified might be lowered by improved training in Epilepsy diagnosis and coding.
-
national and state estimates of the numbers of adults and children with active Epilepsy united states 2015
Morbidity and Mortality Weekly Report, 2017Co-Authors: Matthew M. Zack, Rosemarie KobauAbstract:Epilepsy, a brain disorder leading to recurring seizures, has garnered increased public health focus because persons with Epilepsy experience pronounced and persistent health and socioeconomic disparities despite treatment advances, public awareness programs, and expanded rights for persons with disabilities (1,2). For almost all states, Epilepsy prevalence estimates do not exist. CDC used national data sources including the 2015 National Health Interview Survey (NHIS) for adults (aged ≥18 years), the 2011-2012 National Survey of Children's Health (NSCH), and the 2015 Current Population Survey data, describing 2014 income levels, to estimate prevalent cases of active Epilepsy, overall and by state, to provide information for state public health planning. In 2015, 1.2% of the U.S. population (3.4 million persons: 3 million adults and 470,000 children) reported active Epilepsy (self-reported doctor-diagnosed Epilepsy and under treatment or with recent seizures within 12 months of interview) or current Epilepsy (parent-reported doctor-diagnosed Epilepsy and current Epilepsy). Estimated numbers of persons with active Epilepsy, after accounting for income and age differences by state, ranged from 5,900 in Wyoming to 427,700 in California. NHIS data from 2010-2015 indicate increases in the number of persons with active Epilepsy, probably because of population growth. This study provides updated national and modeled state-specific numbers of active Epilepsy cases. Public health practitioners, health care providers, policy makers, Epilepsy researchers, and other Epilepsy stakeholders, including family members and people with Epilepsy, can use these findings to ensure that evidence-based programs meet the complex needs of adults and children with Epilepsy and reduce the disparities resulting from it.
-
Epilepsy surveillance among adults 19 states behavioral risk factor surveillance system 2005
Morbidity and mortality weekly report. Surveillance summaries (Washington D.C. : 2002), 2008Co-Authors: Rosemarie Kobau, Matthew M. Zack, Hatice S Zahran, David J Thurman, Thomas R Henry, Steven C Schachter, Patricia H PriceAbstract:PROBLEM/CONDITION: Epilepsy is a brain disorder characterized by brief, recurrent disturbances in the normal electrical functions of the brain that result in seizures. Few population-based studies of Epilepsy have been published for the United States, and the prevalence is expected to increase with the aging of the population. This is the first multistate study examining the prevalence of self-reported Epilepsy and active Epilepsy and includes an examination of socioedemographic and behavioral characteristics and of health-related quality of life among adults with Epilepsy. REPORTING PERIOD COVERED: Data from the 2005 Behavioral Risk Factor Surveillance System (BRFSS) are presented for 19 states. DESCRIPTION OF SYSTEM: BRFSS is an ongoing, state-based, random-digit--dialed telephone survey of the noninstitutionalized U.S. population aged >/=18 years. BRFSS collects information on health risk behaviors and preventive health services related to leading causes of death and morbidity. In 2005, 19 states included questions on Epilepsy or seizure disorder. RESULTS/INTERPRETATION: During 2005, 1.65% of noninstitutionalized adults from 19 states reported that they had ever been told by a doctor that they had Epilepsy or seizure disorder (i.e., a history of Epilepsy); 0.84% reported having active Epilepsy (i.e., a history of Epilepsy and currently taking medication or reporting one or more seizures during the past 3 months), and 0.75% were classified as having inactive Epilepsy (i.e., a history of Epilepsy or seizure disorder but currently not taking medicine to control Epilepsy and no seizures in the 3 months preceding the survey). No substantial differences among states in the prevalence of lifetime Epilepsy, active Epilepsy, or inactive Epilepsy were detected. Prevalence estimates for active and inactive Epilepsy revealed no significant differences by sex or race/ethnicity. Adults with a history of Epilepsy and with active Epilepsy were more likely to report fair or poor health, be unemployed or unable to work, live in households with the lowest annual incomes, and have a history of co-occurring disorders (e.g., stroke or arthritis). Adults with a history of Epilepsy and with active Epilepsy also reported significantly worse health-related quality of life. Adults with a history of Epilepsy were more likely to be obese, physically inactive, and current smokers. Among adults with active Epilepsy with recent seizures, 16.1% reported not currently taking their Epilepsy medication, and 65.1% reported having had more than one seizure in the past month. Among adults with a history of Epilepsy, 23.7% reported cost as a barrier to seeking care from a doctor within the past year. A total of 34.9% of adults with active Epilepsy with seizures reported not having seen a neurologist or an Epilepsy specialist (i.e., a neurologist who specializes in treating Epilepsy) in the previous year. PUBLIC HEALTH ACTION: Additional descriptive and analytic studies of Epilepsy occurrence in diverse U.S. communities and populations are needed to better characterize Epilepsy incidence rates, risk factors and etiologies, and types and severity, as well as Epilepsy-associated conditions and disabilities. Community-based strategies that link health- care providers with social services such as public transportation, mental health services, and employment services might improve quality of life in persons with Epilepsy. Implementing educational programs developed by CDC and the Epilepsy Foundation for schools, emergency responders, employers, providers, and the general public can increase awareness about Epilepsy and reduce stigma associated with this disorder.
Yang Lu - One of the best experts on this subject based on the ideXlab platform.
-
altered expression of synaptotagmin i in temporal lobe tissue of patients with refractory Epilepsy
Journal of Molecular Neuroscience, 2009Co-Authors: Zheng Xiao, Zhiqin Xi, Xuefeng Wang, Yun Gong, Fei Xiao, Yang LuAbstract:Synaptotagmin I is a key synaptic protein involved in both exocytosis and endocytosis. We aimed to investigate Synaptotagmin I expression in the anterior temporal neocortex of Epilepsy patients, and to explore the possible role of Synaptotagmin I in refractory Epilepsy. In the present study, 30 Epilepsy patients were divided into refractory Epilepsy and non-refractory Epilepsy groups, another 15 histologically normal anterior temporal lobes from head trauma patients were used as control group. The results were compared among different groups. The findings were consistently observed using immunohistochemistry, immunofluorescence, and Western blotting technique. Synaptotagmin I was mainly expressed in the cytoplasm and cytomembrane of neurons. The expression of Synaptotagmin I in refractory Epilepsy group was significantly higher than that in the control and non-refractory Epilepsy groups. These findings provide new information in the epileptogenesis of refractory Epilepsy, and suggest that Synaptotagmin I might be involved in human refractory Epilepsy. Further studies will be required to elucidate the mechanism by which Synaptotagmin I plays role in refractory Epilepsy.
M. Jovanovic - One of the best experts on this subject based on the ideXlab platform.
-
13.Benign Epilepsy of infancy: Importance of video EEG recording
Clinical Neurophysiology, 2012Co-Authors: B. Jocic-jakubi, M. JovanovicAbstract:Benign epilepsies of infancy are entities for which is not easy to make a diagnosis. In 1963 Fukuyama first proposed the benign epilesy of infancy characterized by onset before the age of 2 years and benign course. Later publications in 80s and 90s specified localization and semiology, familial and nonfamilial characteristics and final outcome. The International classification of epilepsies and epileptic syndromes (Engel, 2001) comprises only familial and non-familial benign infantile seizures. Specchio and Vigevano (2006) described semiology and onset, family history, ictal and interictal EEG pattern, prognosis and final outcome of benign seizures in infancy. They divided them into the following groups: Benign non-familial infantile seizures, Benign familial infantile seizures (BFIS), BFIS associated with other neurological symptoms, Benign familial neonatalinfantile seizures (BFNIS), Benign infantile seizures associated with mild gastroenteritis (BIS with MG), Benign infantile focal Epilepsy with midline spikes and waves during sleep (BIMSE). The aim of this review is to describe these entities and discuss similarities and difference between them. We pointed out significance of video EEG recording in dramatic appearance of seizures in clusters, lasting few days, which can also occured in benign Epilepsy of infancy.
